샘플 요청 목록

 카트 문의
시장보고서
상품코드
1793980

세계의 HIV 관련 지방이영양증 시장

HIV-Associated Lipodystrophy
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 271 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 HIV 관련 지방이영양증 시장은 2030년까지 2억 530만 달러에 달할 전망

2024년에 1억 8,030만 달러로 추정되는 세계의 HIV 관련 지방이영양증 시장은 분석 기간인 2024-2030년에 CAGR 2.2%로 성장하며, 2030년에는 2억 530만 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 경구투여는 CAGR 1.6%를 기록하며, 분석 기간 종료시에는 1억 1,920만 달러에 달할 것으로 예측됩니다. 주사제 투여 부문의 성장률은 분석 기간에 CAGR 3.2%로 추정됩니다.

미국 시장은 4,910만 달러로 추정, 중국은 CAGR 4.2%로 성장 예측

미국의 HIV 관련 지방이영양증 시장은 2024년에 4,910만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년 CAGR을 4.2%로, 2030년까지 3,870만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 0.8%와 1.6%로 예측됩니다. 유럽에서는 독일이 CAGR 1.1%로 성장할 것으로 예측됩니다.

세계의 HIV 관련 지방이영양증 시장 - 주요 동향과 촉진요인 정리

항레트로바이러스 치료의 발전과 함께 HIV 관련 지방이영양증에 대한 임상적 이해는 어떻게 발전하고 있는가?

HIV 관련 지방이영양증은 특히 구세대 항레트로바이러스제로 장기 항레트로바이러스 치료를 받는 환자에서 발생하는 대사적, 미용적 합병증으로 점점 더 많은 관심을 받고 있습니다. 이 병태는 얼굴, 사지, 엉덩이에서 지방이 감소하거나 복부, 경부, 유방에 지방이 축적되는 등 체지방의 비정상적인 분포가 특징입니다. 항레트로바이러스 치료는 HIV 감염인의 생존율과 삶의 질을 크게 향상시켰지만, 리포지드로피는 여전히 신체적, 심리적, 사회적 영향을 미치는 부작용으로 남아있습니다. HIV 연구의 발전으로 미토콘드리아 기능 장애, 사이토카인 불균형, 지방세포 대사의 변화 등 지방변성증의 근본적인 메커니즘을 보다 정교하게 이해할 수 있게 되었습니다. 이제 임상의들은 위험에 처한 환자를 식별할 수 있게 되었으며, 일상적인 HIV 관리에서 리포지디스트로피 스크리닝을 도입하고 있습니다. 이 병태가 단순한 미용상의 문제가 아니라는 인식이 지방의 재분포 패턴, 인슐린 저항성, 이상지질혈증, 심혈관 위험과 같은 관련 대사 장애를 모니터링하려는 노력에 힘을 실어주고 있습니다. 치료 전략은 환자프로파일, 약물 이력, 증상 정도에 따라 개별화되어 가고 있습니다. 안전성 프로파일이 개선된 새로운 항레트로바이러스제는 중증 지방 재분포의 발생률을 낮추는데 도움이 되고 있지만, 이미 발병한 환자에게는 여전히 큰 도전이 되고 있습니다. 임상 프로토콜이 계속 발전하고 있는 가운데, 지방증후군이 건강과 웰빙에 미치는 장기적인 영향을 줄이기 위해 조기 발견, 지속적인 모니터링, 지질 관리 전략의 통합이 우선순위가 되고 있습니다.

HIV 관련 지방이영양증의 복잡한 증상에 대처하기 위해 어떤 치료법이 등장하고 있는가?

HIV 관련 지방이영양증의 관리는 약리학적, 외과적, 생활습관 기반 중재를 결합하여 신체적 증상과 기저에 있는 대사 불균형에 대처하기 위한 다각적인 시도가 이루어지고 있습니다. 약리학적 전략은 리포지드로피증을 악화시키는 것으로 알려진 오래된 항레트로바이러스제에서 대사 부작용이 적은 새로운 항레트로바이러스제로 전환하는 것을 포함하여 개선되고 있습니다. 현재는 인테그라제 억제제나 2세대 프로테아제 억제제 등의 약물이 지방 재분포의 위험을 줄이면서 바이러스를 억제할 수 있으며, 선호되고 있습니다. 지방 위축증에서는 폴리유산이나 히알루론산을 함유한 더말 필러가 얼굴의 볼륨을 회복하고 자기 이미지에 대한 심리적 결과를 개선하기 위해 사용됩니다. 지방이 축적된 환자에게는 성장호르몬 방출인자 유사체인 테사모렐린과 같은 접근법이 내장지방조직을 감소시키는데 효과적인 것으로 나타났습니다. 또한 체중 관리와 체성분 개선을 목적으로 영양계획, 운동요법 등 생활습관 개선에 대한 개입도 이루어지고 있습니다. 지방흡입술이나 지방이식술과 같은 수술적 치료는 더 심한 경우에는 가능하지만, 일반적으로 보존적 치료에 반응하지 않는 환자들에게만 제한적으로 시행됩니다. 또한 지방세포의 분화와 염증을 표적으로 하는 새로운 치료법이 임상시험을 통해 검토되고 있으며, 향후 장기적인 해결책을 제시할 수 있을 것으로 보입니다. 이 질환의 다면적 특성으로 인해 종합적인 치료를 제공하기 위해서는 내분비 전문의, 감염 전문의, 성형외과 전문의, 정신과 전문의 등 다양한 분야의 전문가들이 협력하여 접근해야 합니다. 이러한 다학제적 대응은 환자가 자신의 몸을 통제할 수 있는 감각을 되찾고 치료 순응도를 유지하는 데 매우 중요합니다.

지방이영양증의 심리사회적 영향은 환자 중심의 HIV 치료 모델을 어떻게 형성하고 있는가?

HIV 관련 지방이영양증의 심리사회적 부담은 HIV 감염인의 치료 순응도, 정신건강, 삶의 질에 영향을 미치는 핵심적인 요인으로 인식되고 있습니다. 주로 체내에서 발생하는 다른 HIV 관련 합병증과 달리, 지방이영양증은 눈에 보이는 형태로 나타나며 종종 낙인, 수치심, 사회적 은둔으로 이어지기도 합니다. 외모의 변화, 특히 얼굴의 쇠퇴와 중심부의 지방 축적은 항상 질병을 상기시켜 환자의 자존감과 사회적 자신감을 떨어뜨립니다. 이러한 정신적 부담은 특히 HIV에 대한 낙인이 큰 지역에서는 사회적 오해와 정보 공개에 대한 두려움으로 인해 더욱 커질 수 있습니다. 그 결과, 많은 환자들이 불안, 우울증, 신체 이미지 문제로 어려움을 겪으며 약물 순응도 및 전반적인 건강 결과에 부정적인 영향을 미칠 수 있습니다. 이에 반해 의료진들은 HIV 치료의 심리적, 사회적 측면을 더 중요시하고 있습니다. 상담 서비스, 동료 지원 네트워크, 교육 워크숍이 치료 프로그램에 통합되어 환자에게 대화와 대처 전략을 위한 안전한 공간을 제공합니다. 원격의료 플랫폼은 또한 지속적인 참여를 촉진하고 임상의가 신체적, 정신적 건강을 모두 모니터링할 수 있도록 돕습니다. 환자 지원 단체와 지역사회 단체의 부상은 지방이영양증에 대한 인식을 높이고, 재건 치료에 대한 폭넓은 접근과 종합적인 치료 정책을 촉진하고 있습니다. 의료 시스템이 HIV 감염인의 전인적 필요를 충족시키기 위해 노력함에 따라 지방이영양증의 심리사회적 측면을 다루는 것은 더 이상 후순위로 밀려나지 않고, 효과적이고 배려심 있는 HIV 관리의 핵심 요소로 자리 잡았습니다.

HIV 관련 지방이영양증 치료제 시장의 성장을 이끄는 주요 요인은 무엇인가?

HIV 관련 지방이영양증 치료 시장의 성장은 의료, 기술, 인구통계학적, 사회적 요인이 복합적으로 작용하여 전 세계에서 HIV 치료의 형태를 변화시키고 있습니다. 주요 요인 중 하나는 장기 HIV 생존자 인구가 증가하고 있으며, 이들 중 상당수가 지방이영양증에 걸리기 쉬운 오래된 항레트로바이러스 요법에 노출되어 있다는 점입니다. 이러한 사람들이 고령화됨에 따라 지방의 재분포와 그에 따른 대사적 합병증의 장기적인 영향으로 인해 전문적인 치료에 대한 수요가 증가하고 있습니다. 의약품 개발의 발전도 큰 역할을 하고 있으며, 제약회사들은 보다 안전한 항레트로바이러스 요법이나 지방 축적을 직접적으로 표적으로 삼는 테사모렐린과 같은 보조제를 출시하고 있습니다. 저장성 영양장애의 중요성에 대한 의료 전문가들의 인식이 높아짐에 따라 조기 진단과 적극적인 개입이 이루어지고 있으며, 이는 시장 성장에 기여하고 있습니다. 국제적인 자금 지원과 공중보건 구상에 힘입어 신흥 시장에서의 의료 접근성이 확대되면서 이전에는 보고되지 않았던 HIV 관련 질환의 진단과 치료가 더욱 가능해졌습니다. 과거에는 임의 치료나 사치스러운 치료로 여겨졌던 미용 및 재건 치료도 의료적으로 필요한 치료로 간주되어 일부 지역에서는 보험사로부터 환급을 받을 수 있게 되었습니다. 또한 환자 옹호 및 교육 캠페인을 통해 치료를 받도록 독려하고, 낙인을 줄여 시장 침투력을 높이고 있습니다. 내분비학, 감염 전문가, 피부과, 정신건강의학과를 결합한 다학제적 치료 모델의 통합은 치료 접근법의 효과를 높이고 환자의 치료 결과와 장기적인 순응도를 향상시키고 있습니다. 이러한 요인들이 결합되어 임상적 효과와 환자의 존엄성을 모두 충족하는 HIV 관련 지방이영양증 관리를 위한 보다 신속하고 진화한 시장을 조성하고 있습니다.

부문

투여 경로(경구투여, 주사 투여, 기타 투여 경로), 유통 채널(병원 약국, 소매 약국, 온라인 유통 채널)

조사 대상 기업의 예

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GSK plc(formerly GlaxoSmithKline)
  • Janssen Global Services, LLC(A Johnson & Johnson Company)
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche(F. Hoffmann-La Roche Ltd.)
  • Sanofi S.A.
  • Theratechnologies Inc.
  • Takeda Pharmaceutical Company Limited
  • ViiV Healthcare Limited(a joint venture of GSK, Pfizer, and Shionogi)

AI 통합

검증된 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁합니다.

Global Industry Analysts는 일반적인 LLM나 업계 고유 SLM에 쿼리 하는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.28

Global HIV-Associated Lipodystrophy Market to Reach US$205.3 Million by 2030

The global market for HIV-Associated Lipodystrophy estimated at US$180.3 Million in the year 2024, is expected to reach US$205.3 Million by 2030, growing at a CAGR of 2.2% over the analysis period 2024-2030. Oral Administration, one of the segments analyzed in the report, is expected to record a 1.6% CAGR and reach US$119.2 Million by the end of the analysis period. Growth in the Injectable Administration segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$49.1 Million While China is Forecast to Grow at 4.2% CAGR

The HIV-Associated Lipodystrophy market in the U.S. is estimated at US$49.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$38.7 Million by the year 2030 trailing a CAGR of 4.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.

Global HIV-Associated Lipodystrophy Market - Key Trends & Drivers Summarized

How Is the Clinical Understanding of HIV-Associated Lipodystrophy Evolving with Advancements in Antiretroviral Therapy?

HIV-associated lipodystrophy is increasingly gaining attention as both a metabolic and cosmetic complication that arises in individuals undergoing long-term antiretroviral therapy, particularly with older generation drugs. This condition is characterized by abnormal distribution of body fat, including fat loss from the face, limbs, and buttocks, or fat accumulation in the abdomen, neck, and breasts. While antiretroviral therapy has drastically improved survival rates and quality of life for people living with HIV, lipodystrophy remains a persistent side effect that carries physical, psychological, and social implications. Advances in HIV research have led to a more refined understanding of the underlying mechanisms of lipodystrophy, which include mitochondrial dysfunction, cytokine imbalances, and alterations in adipocyte metabolism. Clinicians are now better able to identify patients at risk and are incorporating lipodystrophy screening into routine HIV management. The recognition of this condition as more than just a cosmetic issue has driven efforts to monitor fat redistribution patterns and associated metabolic disturbances such as insulin resistance, dyslipidemia, and cardiovascular risk. Treatment strategies are increasingly being individualized based on patient profiles, drug history, and extent of symptoms. Newer antiretroviral drugs with improved safety profiles are helping reduce the incidence of severe fat redistribution, though the challenge remains substantial for those already affected. As clinical protocols continue to evolve, early detection, ongoing monitoring, and integration of lipid management strategies are being prioritized to mitigate the long-term impact of lipodystrophy on health and well-being.

What Treatment Modalities Are Emerging to Address the Complex Symptoms of HIV-Associated Lipodystrophy?

The management of HIV-associated lipodystrophy has become a multifaceted endeavor, combining pharmacological, surgical, and lifestyle-based interventions to address both the physical symptoms and the underlying metabolic imbalances. Pharmacological strategies are being refined to include switching from older antiretroviral agents known to exacerbate lipodystrophy to newer classes with fewer metabolic side effects. Agents such as integrase inhibitors and second-generation protease inhibitors are now preferred, as they offer viral suppression with a reduced risk of fat redistribution. In cases of lipoatrophy, dermal fillers including polylactic acid and hyaluronic acid are being employed to restore facial volume and improve psychological outcomes related to self-image. For patients experiencing fat accumulation, approaches such as tesamorelin, a growth hormone-releasing factor analog, have demonstrated effectiveness in reducing visceral adipose tissue. Lifestyle interventions involving targeted nutrition plans and exercise regimens are also being prescribed to manage weight and improve body composition. Surgical options like liposuction or fat grafting remain available for more severe cases, though they are generally reserved for patients who do not respond to conservative treatments. Additionally, emerging therapies targeting adipocyte differentiation and inflammation are under investigation in clinical trials, potentially offering long-term solutions in the future. The multidimensional nature of the condition requires a collaborative approach involving endocrinologists, infectious disease specialists, plastic surgeons, and mental health professionals to provide comprehensive care. This multidisciplinary response is critical in helping patients regain a sense of control over their bodies and maintain treatment adherence.

How Is the Psychosocial Impact of Lipodystrophy Shaping Patient-Centered HIV Care Models?

The psychosocial burden of HIV-associated lipodystrophy is increasingly recognized as a central factor influencing treatment adherence, mental health, and quality of life among people living with HIV. Unlike other HIV-related complications that are primarily internal, lipodystrophy manifests visibly, often leading to stigma, embarrassment, and social withdrawal. Changes in physical appearance, especially facial wasting or central fat accumulation, can become constant reminders of the disease, undermining a patient’s self-esteem and social confidence. This emotional toll is compounded by societal misconceptions and the fear of disclosure, especially in regions where HIV remains heavily stigmatized. As a result, many patients struggle with anxiety, depression, and body image issues, which can negatively affect medication compliance and overall health outcomes. In response, healthcare providers are placing greater emphasis on the psychological and social dimensions of HIV care. Counseling services, peer support networks, and educational workshops are being integrated into treatment programs to offer patients a safe space for dialogue and coping strategies. Telehealth platforms are also facilitating continuous engagement, allowing clinicians to monitor both physical and emotional well-being. The rise of patient advocacy groups and community organizations is amplifying awareness about the lived experience of lipodystrophy, pushing for broader access to reconstructive treatments and inclusive care policies. As health systems become more attuned to the holistic needs of people with HIV, addressing the psychosocial aspects of lipodystrophy is no longer an afterthought but a core component of effective, compassionate HIV management.

What Key Factors Are Driving the Growth of the HIV-Associated Lipodystrophy Treatment Market?

The growth in the HIV-associated lipodystrophy treatment market is driven by a combination of medical, technological, demographic, and social factors that are reshaping HIV care globally. One of the primary drivers is the growing population of long-term HIV survivors, many of whom were exposed to older antiretroviral regimens that predisposed them to lipodystrophy. As these individuals age, the long-term effects of fat redistribution and associated metabolic complications are prompting increased demand for specialized treatments. Advances in drug development are also playing a major role, with pharmaceutical companies introducing safer antiretroviral therapies and adjunctive medications like tesamorelin that directly target fat accumulation. Rising awareness among healthcare professionals about the significance of lipodystrophy is leading to earlier diagnosis and proactive intervention, which is supporting market growth. The expansion of healthcare access in emerging markets, aided by international funding and public health initiatives, is further enabling diagnosis and treatment of HIV-related conditions that were previously underreported. Cosmetic and reconstructive treatments, once considered optional or luxury interventions, are being increasingly viewed as medically necessary, thereby attracting reimbursement from insurance providers in some regions. Additionally, patient advocacy and education campaigns are encouraging individuals to seek treatment, reducing stigma and improving market penetration. The integration of multidisciplinary care models that combine endocrinology, infectious disease expertise, dermatology, and mental health is enhancing the effectiveness of treatment approaches, driving better patient outcomes and long-term adherence. Together, these drivers are fostering a more responsive and evolving marketplace for managing HIV-associated lipodystrophy with both clinical efficacy and patient dignity at its center.

SCOPE OF STUDY:

The report analyzes the HIV-Associated Lipodystrophy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Oral Administration, Injectable Administration, Other Administration Routes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GSK plc (formerly GlaxoSmithKline)
  • Janssen Global Services, LLC (A Johnson & Johnson Company)
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche (F. Hoffmann-La Roche Ltd.)
  • Sanofi S.A.
  • Theratechnologies Inc.
  • Takeda Pharmaceutical Company Limited
  • ViiV Healthcare Limited (a joint venture of GSK, Pfizer, and Shionogi)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • HIV-Associated Lipodystrophy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing HIV Patient Population Under Long-Term ART Therapy Throws the Spotlight on Lipodystrophy as a Chronic Complication
    • Increased Awareness Among Clinicians and Patients Propels Early Diagnosis and Targeted Intervention
    • Rising Demand for Body Fat Redistribution Therapies Strengthens Business Case for Specialized Treatments
    • Advancements in Antiretroviral Drug Formulations Drive Reduction in Lipodystrophy Risk but Sustain Market for Legacy Patients
    • Expansion of Aesthetic and Reconstructive Treatment Options Spurs Interest in Cosmetic Management of Facial Lipoatrophy
    • Novel Therapies Accelerate Access to Lipodystrophy-Specific Medications
    • Psychosocial Impact of Disfigurement Generates Demand for Holistic and Mental Health-Integrated Treatment Plans
    • R&D in Adipogenesis and Metabolic Pathway Modulation Throws the Spotlight on Innovative Therapeutic Mechanisms
    • Growing Use of Injectable Poly-L-Lactic Acid and Dermal Fillers Expands Non-Surgical Treatment Options
    • Increased Insurance Coverage and Reimbursement Support Drives Market Accessibility for Approved Treatments
    • Limited Availability of Biomarkers and Diagnostic Tools Poses Challenges to Personalized Lipodystrophy Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World HIV-Associated Lipodystrophy Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for HIV-Associated Lipodystrophy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for HIV-Associated Lipodystrophy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for HIV-Associated Lipodystrophy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for HIV-Associated Lipodystrophy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for HIV-Associated Lipodystrophy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for HIV-Associated Lipodystrophy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for HIV-Associated Lipodystrophy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for HIV-Associated Lipodystrophy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for HIV-Associated Lipodystrophy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for HIV-Associated Lipodystrophy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • HIV-Associated Lipodystrophy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for HIV-Associated Lipodystrophy by Administration Route - Oral Administration, Injectable Administration and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for HIV-Associated Lipodystrophy by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Other Administration Routes for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for HIV-Associated Lipodystrophy by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for HIV-Associated Lipodystrophy by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제